INTERET DU DOSAGE DU HER-2 EN CANCEROLOGIE (Cas des cancers: de l’estomac, de l’ovaire et de la vessie)

Abstract

Despite a reduction of mortality in the world, cancer still present a major problem Public Health and one of the most frequent causes deaths. In the primary cancer or metastatic setting the goal of treatment is to control symptoms, improve quality of life and prolong survival, but some current treatment protocols have limited the effectiveness of their unfavorable toxicity profiles. These observations suggest the need for new therapeutic approaches that are based on the targeted therapy e. Several studies have shown that the regulation of signaling pathways family of epidermal growth factor receptor plays a central role in cell differentiation, proliferation, survival and supported the development of antitumor strategies against these targets. One of the most significant innovative targets HER2 (Human epidermal receptor 2). There are far larger studies examining the prognostic significance of HER2 expression in cancers in exploring as a prognostic marker (such as gastric metastatic HER-2 positive). HER2a protein of 185 kDa (p185) encoded by a gene located on chromosome 17q21, is a receptor tyrosine kinase (TK). The objective of our work is to study the clinicopathological profile of a set of cancer: cancer of the stomach, ovary and bladder and study overexpression and HER2 gene amplification in these cancers through immunohistochemistry and other molecular biology techniques: by Fluorescence in Situ Hybridization (FISH).